Ticker > Company >

Novelix Pharma share price

Novelix Pharmaceuticals Ltd.

BSE: 536565 SECTOR: Trading  5.4 K   6   1

50.50
+0.47 (0.94%)
BSE: 14 Jul 04:01 PM

Price Summary

Today's High

₹ 52.53

Today's Low

₹ 47.55

52 Week High

₹ 51.25

52 Week Low

₹ 19.88

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

65.32 Cr.

Enterprise Value

65.2 Cr.

No. of Shares

1.29 Cr.

P/E

786.6

P/B

2.78

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  18.17

CASH

0.12 Cr.

DEBT

0 Cr.

Promoter Holding

52.75 %

EPS (TTM)

₹  0.06

Sales Growth

200.72%

ROE

0.14 %

ROCE

0.3%

Profit Growth

117.38 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year200.72%
3 Year61.28%
5 Year3.29%

Profit Growth

1 Year433.02%
3 Year27.01%
5 Year-8.58%

ROE%

1 Year0.14%
3 Year-6.71%
5 Year-10.13%

ROCE %

1 Year0.3%
3 Year-6.67%
5 Year-10.09%

Debt/Equity

0

Price to Cash Flow

-190.17

Interest Cover Ratio

79.7333

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 52.75 0.00
Mar 2025 66.56 0.00
Dec 2024 66.56 0.00
Sep 2024 66.56 0.00
Jun 2024 66.54 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 61.2814545233371% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy liquidity position with current ratio of 407.4386.
  • The company has a high promoter holding of 52.75%.

 Limitations

  • Company has a poor ROE of -6.71146200683163% over the past 3 years.
  • Company has a poor ROCE of -6.674917931136% over the past 3 years
  • Company has negative cash flow from operations of -0.343491.
  • The company has a low EBITDA margin of -132.356876131638% over the past 5 years.
  • The company is trading at a high PE of 786.6.
  • The company is trading at a high EV/EBITDA of 404.0172.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 0.84 0.6 3.96 5.3 20.86
Total Expenditure 0.69 1.04 3.74 5.17 20.63
Operating Profit 0.16 -0.44 0.22 0.13 0.23
Other Income 0.13 0.1 -0.08 0 0
Interest 0 0 0 0 0
Depreciation 0.01 0.01 0.01 0.01 0.02
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.28 -0.35 0.13 0.13 0.21
Tax 0 0.01 0 -0.02 0.03
Profit After Tax 0.28 -0.35 0.13 0.15 0.18
Adjusted EPS (Rs) 0.34 -0.36 0.13 0.15 0.18

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1.03 1.01 0.84 1.4 4.22
Total Expenditure 1.32 4.52 2.89 1.92 4.47
Operating Profit -0.29 -3.51 -2.05 -0.52 -0.25
Other Income 0.47 0.32 0.55 0.52 0.31
Interest 0 0 0 0 0
Depreciation 0.08 0.08 0.07 0.06 0.04
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.11 -3.27 -1.57 -0.06 0.02
Tax 0.01 0 -0.01 0 0.01
Net Profit 0.06 -3.27 -1.56 -0.05 0.16
Adjusted EPS (Rs.) 0.12 -4.04 -1.93 -0.07 0.01

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 8.1 8.1 8.1 8.1 8.1
Total Reserves 3.97 0.7 -0.86 -0.9 -0.75
Borrowings 0 0 0 0 0
Other N/C liabilities -0.06 -0.06 -0.07 -0.06 -0.05
Current liabilities 0.03 0.02 0.01 0.06 0.01
Total Liabilities 12.04 8.77 7.19 7.19 7.31
Assets
Net Block 0.31 0.22 0.23 0.17 0.12
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 3.53 3.64 0.59 2.78 3.06
Loans & Advances 0.2 0.2 0 0 0
Other N/C Assets 0 0 1.74 0 0
Current Assets 8 4.7 4.63 4.24 4.13
Total Assets 12.04 8.77 7.19 7.19 7.31
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 0.11 -3.27 -1.57 -0.06 0.02
Adjustment -0.36 -0.24 1.04 -0.46 -0.27
Changes in Assets & Liabilities 1.51 4.09 1.12 -1.89 -0.1
Tax Paid 0 0 0 0 0
Operating Cash Flow 1.21 0.58 0.59 -2.41 -0.34
Investing Cash Flow -0.42 0.21 0.28 0.08 0.19
Financing Cash Flow 0 0 0 0 0
Net Cash Flow 0.79 0.78 0.87 -2.33 -0.16

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 66.54 66.56 66.56 66.56 52.75
gattu gnana prakash - - - - 2.71
narhari belide - - - - 1.55
srinidhi fine-chemicals l... - - - - 38.67
vupparapalli chandrasekha... - - - - 6.73
vupparapalli pavani - - - - 3.09
gattu gnana prakash 3.52 3.52 3.52 3.52 -
srinidhi fine chemicals l... - - - 50.27 -
vupparapalli chandrasekha... 8.75 8.75 8.75 8.75 -
vupparapalli pavani 4.02 4.02 4.02 4.02 -
srinidhi fine-chemicals l... 50.25 50.27 50.27 - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 33.46 33.44 33.44 33.44 47.25
dm fincon services llp - - - - 1.93
investor education and pr... 1.36 - 1.36 1.36 1.04
mallela venkatramna reddy... - - - - 11.60
medo capital services pri... - - - - 0.97
panchagnula venkata laksh... - - - - 2.90
sesha sai nikhil chintala... - - - - 2.32
soura investments holding... - - - - 2.09
srinivasrao swetha kanaka... - - - - 2.32
tdpl health care (india) ... - - - - 2.71
dm fincon services llp 2.51 2.51 2.51 2.51 -
medo capital services pri... - 1.26 1.26 1.26 -
panchagnula venkata laksh... 2.26 2.26 2.26 2.26 -
sesha sai nikhil chintala... 1.01 - - 1.01 -
soura investments holding... 2.71 2.71 2.71 2.71 -
srinivasrao swetha kanaka... - 1.01 1.01 1.01 -
tdpl health care (india) ... 3.52 3.52 3.52 3.52 -
sesha sai nikhil chintal... - 1.01 1.01 - -
investor education and pr... - 1.36 - - -
k s swetha 1.01 - - - -
kamal kishore bung 1.26 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Novelix Pharmaceuticals informs about board meeting 21 Jun, 3:40 PM Novelix Pharma - Quaterly Results 27 May, 6:09 PM Novelix Pharma - Quaterly Results 27 May, 6:09 PM Trimurthi - Quaterly Results 13 Feb, 6:08 PM Trimurthi - Quaterly Results 13 Feb, 6:08 PM Trimurthi informs about disclosure 17 Sep, 10:58 AM Trimurthi informs about disclosure 17 Sep, 10:54 AM Trimurthi informs about disclosure 17 Sep, 10:53 AM Trimurthi informs about disclosure 17 Sep, 10:52 AM Trimurthi informs about press release 12 Sep, 1:50 PM Trimurthi - Quaterly Results 8 Aug, 1:16 PM Trimurthi - Quaterly Results 8 Aug, 1:16 PM Trimurthi informs about disclosure 13 Jun, 10:31 AM Trimurthi - Quaterly Results 28 May, 4:53 PM Trimurthi informs about open offer 5 Mar, 5:20 PM Trimurthi - Quaterly Results 30 Jan, 2:27 PM Trimurthi - Quaterly Results 30 Jan, 2:27 PM Trimurthi - Quaterly Results 30 Jan, 2:27 PM Trimurthi - Quaterly Results 17 Oct, 4:14 PM Trimurthi - Quaterly Results 17 Oct, 4:14 PM Trimurthi - Quaterly Results 17 Oct, 4:14 PM Trimurthi informs about outcome of AGM 15 Sep, 5:16 PM Trimurthi informs about update on outcome of board meeting 10 Aug, 5:07 PM Trimurthi - Quaterly Results 9 Aug, 4:39 PM Trimurthi - Quaterly Results 9 Aug, 4:39 PM Trimurthi - Quaterly Results 9 Aug, 4:39 PM Trimurthi informs about annual report 25 May, 5:52 PM Trimurthi - Quaterly Results 29 Apr, 5:15 PM Trimurthi - Quaterly Results 29 Apr, 5:15 PM Trimurthi - Quaterly Results 29 Apr, 5:15 PM Trimurthi sells holding in Curova India LLP 16 Mar, 5:47 PM Trimurthi - Quaterly Results 9 Feb, 4:12 PM Trimurthi - Quaterly Results 9 Feb, 4:12 PM Trimurthi - Quaterly Results 9 Feb, 4:12 PM Trimurthi informs about board meeting 1 Feb, 4:43 PM Trimurthi transfers entire stake in Trimurthi Pharmaceuticals 6 Oct, 12:38 PM Trimurthi - Quaterly Results 10 Aug, 5:03 PM Trimurthi informs about closure of trading window 28 Mar, 4:05 PM Trimurthi sells entire stake in Trimurthi Foods 26 Mar, 11:01 AM Trimurthi informs about outcome board meeting 27 Jan, 5:23 PM Trimurthi informs about certificate 29 Apr, 12:03 PM Trimurthi informs about disclosure 15 Mar, 3:31 PM Trimurthi to consider un-audited financial results 30 Jan, 4:14 PM

Novelix Pharma Stock Price Analysis and Quick Research Report. Is Novelix Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Novelix Pharma stock price today is Rs 50.5. Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Novelix Pharma . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Novelix Pharma has a PE ratio of 786.604361370716 which is high and comparatively overvalued .

  • Share Price: - The current share price of Novelix Pharma is Rs 50.5. One can use valuation calculators of ticker to know if Novelix Pharma share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Novelix Pharma has ROA of 0.1436 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Novelix Pharma has a Current ratio of 407.4386 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Novelix Pharma has a ROE of 0.1431 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Novelix Pharma has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Novelix Pharma has reported revenue growth of 200.7188 % which is fair in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Novelix Pharma for the current financial year is -5.86477465520334 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Novelix Pharma is Rs 0 and the yield is 0 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Novelix Pharma is Rs 0.0642 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Novelix Pharma in Ticker for free. Also, one can get the intrinsic value of Novelix Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Novelix Pharma
X